Developmental perfluorooctane sulfonic acid exposure exacerbates house dust mite induced allergic responses in adult mice.

Joseph H Lucas, Qixin Wang, Cortney Pang, Irfan Rahman
Author Information
  1. Joseph H Lucas: Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.
  2. Qixin Wang: Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.
  3. Cortney Pang: Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.
  4. Irfan Rahman: Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: irfan_rahman@urmc.rochester.edu.

Abstract

Perfluorooctane sulfonic acid (PFOS) is a long-chain per- and polyfluoroalkyl substance (PFAS), a persistent organic pollutant, which has been used in aqueous film-forming foams. Emerging epidemiological evidence indicates a significant body burden of PFOS is observed in the lungs. Furthermore, developmental PFOS exposure dysregulates lung development and exacerbates eosinophilic inflammation, which are critical risk factors for asthma. However, it is unknown whether PFOS exerts sex-dependent effects on house dust mite (HDM) induced asthmatic progression and allergic inflammation. In this study, timed pregnant Balb/cJ dams were dosed orally via PFOS (1.0 mg/kg/d) spiked or vehicle control mealworms from gestational day (GD) 0.5 to postnatal day (PND) 21. Subsequently, HDM (30 μg/day) was administered starting at PND 77-82 for 10 days, and the mice were sacrificed 48 h after their final treatment. The serum and lung PFOS concentrations were 3.391 ± 0.189 μg/mL and 3.567 ± 0.1676 μg/g in the offspring, respectively. Male mice exposed to PFOS + HDM showed higher total cell counts in bronchoalveolar lavage fluid (BALF), macrophage counts, and eosinophil counts compared to mice exposed to HDM alone. Female mice exposed to PFOS + HDM had increased BALF eosinophil percentage, mucous production, alternatively activated (M2) macrophage polarization, and M2-associated gene expression compared to female mice exposed to HDM alone. PFOS exposure had no significant effect on HDM-induced IL-4, IL-5, or IL-13, but RANTES was further elevated in female mice. Overall, our data suggest that developmental PFOS exposure increased the risk of exacerbated eosinophilic inflammation and M2 polarization, which were more severe in female mice, suggesting sex-dependent developmental effects of PFOS on allergic airway responses.

Keywords

References

  1. Toxics. 2021 Jul 14;9(7): [PMID: 34357911]
  2. J Neuroendocrinol. 2022 Jun;34(6):e13082 [PMID: 35000221]
  3. Int J Mol Sci. 2020 Oct 26;21(21): [PMID: 33114551]
  4. Environ Health Perspect. 2007 Nov;115(11):1596-602 [PMID: 18007991]
  5. Toxicol In Vitro. 2020 Feb;62:104656 [PMID: 31536757]
  6. Sci Total Environ. 2021 Apr 20;766:142365 [PMID: 33601665]
  7. J Allergy Clin Immunol Pract. 2023 Mar;11(3):811-821.e5 [PMID: 36473624]
  8. Cells. 2021 Feb 18;10(2): [PMID: 33670759]
  9. Lancet. 2020 Oct 17;396(10258):1204-1222 [PMID: 33069326]
  10. Pediatr Res. 2016 Feb;79(2):348-57 [PMID: 26492286]
  11. Front Toxicol. 2022 Aug 29;4:971970 [PMID: 36105436]
  12. Reprod Toxicol. 2009 Jun;27(3-4):239-245 [PMID: 19429402]
  13. Eur Respir J. 2017 Sep 12;50(3): [PMID: 28899935]
  14. PLoS One. 2019 May 8;14(5):e0216056 [PMID: 31067281]
  15. Pharmacol Res Perspect. 2021 May;9(3):e00770 [PMID: 33929099]
  16. PLoS Biol. 2017 Dec 20;15(12):e2002855 [PMID: 29261653]
  17. Int J Hyg Environ Health. 2020 Aug;229:113565 [PMID: 32485600]
  18. Lancet Respir Med. 2020 Nov;8(11):1094-1105 [PMID: 32220282]
  19. Eur J Pharmacol. 2020 Jun 15;877:173090 [PMID: 32234529]
  20. Environ Res. 2021 Jan;192:110178 [PMID: 32991923]
  21. Inhal Toxicol. 2022;34(9-10):244-259 [PMID: 35704474]
  22. Ann Am Thorac Soc. 2018 Mar;15(3):348-356 [PMID: 29323930]
  23. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 15;307(10):L765-74 [PMID: 25217661]
  24. Environ Res. 2019 Feb;169:114-121 [PMID: 30447498]
  25. Environ Sci Process Impacts. 2020 Oct 1;22(10):2023-2030 [PMID: 32940316]
  26. Environ Pollut. 2021 Apr 15;275:116619 [PMID: 33578314]
  27. Toxicol Sci. 2024 Jun 26;200(1):57-69 [PMID: 38603627]
  28. Am J Respir Cell Mol Biol. 2016 Oct;55(4):467-475 [PMID: 27248771]
  29. J Allergy Clin Immunol Glob. 2023 Jul 24;2(4):100155 [PMID: 37781650]
  30. Immunity. 2010 Nov 24;33(5):699-712 [PMID: 21093321]
  31. J Allergy Clin Immunol. 2010 Sep;126(3):498-504.e1-6 [PMID: 20816186]
  32. Environ Health Perspect. 2013 Apr;121(4):507-13 [PMID: 23309686]
  33. Arch Toxicol. 2018 Feb;92(2):705-716 [PMID: 29063134]
  34. Int J Mol Sci. 2023 May 10;24(10): [PMID: 37239886]
  35. Ital J Pediatr. 2018 Dec 22;44(1):151 [PMID: 30579359]
  36. Sci Immunol. 2017 Mar 10;2(9): [PMID: 28783701]
  37. J Immunotoxicol. 2021 Dec;18(1):105-117 [PMID: 34455897]
  38. Environ Health Perspect. 2007 Sep;115(9):1298-305 [PMID: 17805419]
  39. Birth Defects Res B Dev Reprod Toxicol. 2005 Oct;74(5):405-16 [PMID: 16249997]
  40. Toxicol Appl Pharmacol. 2022 Aug 15;449:116136 [PMID: 35752307]
  41. Environ Pollut. 2021 Mar 1;272:115535 [PMID: 33223333]
  42. Sci Adv. 2020 Oct 21;6(43): [PMID: 33087360]
  43. World J Pediatr. 2023 Jun;19(6):549-556 [PMID: 36857022]
  44. MMWR Surveill Summ. 2021 Sep 17;70(5):1-32 [PMID: 34529643]
  45. Environ Int. 2019 Mar;124:462-472 [PMID: 30684804]
  46. Health Qual Life Outcomes. 2015 Feb 13;13:21 [PMID: 25879643]
  47. Am J Respir Crit Care Med. 2018 Feb 1;197(3):313-324 [PMID: 29064281]
  48. Arch Toxicol. 2009 Sep;83(9):805-15 [PMID: 19343326]
  49. Neurotoxicol Teratol. 2016 Jul-Aug;56:75-80 [PMID: 27094606]
  50. J Cell Physiol. 2018 Sep;233(9):6425-6440 [PMID: 29319160]
  51. Chemosphere. 2012 Sep;88(11):1269-75 [PMID: 22494529]
  52. Lancet. 2023 May 20;401(10389):1669-1680 [PMID: 37086744]
  53. Toxicology. 2009 Aug 21;262(3):207-14 [PMID: 19540903]
  54. Eur Respir Rev. 2021 Nov 17;30(162): [PMID: 34789462]
  55. Front Immunol. 2022 Dec 20;13:1056477 [PMID: 36605195]
  56. Exp Mol Med. 2017 Aug 4;49(8):e364 [PMID: 28775365]
  57. Biol Reprod. 1979 May;20(4):733-8 [PMID: 454763]
  58. Am J Epidemiol. 2009 Nov 15;170(10):1268-78 [PMID: 19846564]
  59. Front Public Health. 2022 Nov 03;10:1059195 [PMID: 36408054]
  60. Proc Natl Acad Sci U S A. 2021 Jun 15;118(24): [PMID: 34099560]
  61. Toxics. 2021 Dec 09;9(12): [PMID: 34941779]
  62. Nat Commun. 2021 May 18;12(1):2915 [PMID: 34006824]
  63. EBioMedicine. 2016 Jul;9:61-76 [PMID: 27374313]
  64. Toxicol Sci. 2022 Nov 23;190(2):215-226 [PMID: 36106993]
  65. J Allergy Clin Immunol. 2020 Jun;145(6):1641-1654 [PMID: 32305348]
  66. Sci Rep. 2018 Mar 23;8(1):5105 [PMID: 29572536]
  67. Transl Pediatr. 2020 Jun;9(3):210-212 [PMID: 32775238]
  68. Front Immunol. 2018 Dec 18;9:2997 [PMID: 30619350]
  69. Toxicol Sci. 2024 Jun 03;: [PMID: 38830033]
  70. Arch Toxicol. 2011 Oct;85(10):1235-44 [PMID: 21327619]
  71. Environ Sci Technol. 2014 Apr 1;48(7):3864-74 [PMID: 24588690]
  72. J Clin Invest. 2023 Oct 2;133(19): [PMID: 37781922]

Grants

  1. R01 ES029177/NIEHS NIH HHS
  2. T32 ES007026/NIEHS NIH HHS

MeSH Term

Animals
Fluorocarbons
Alkanesulfonic Acids
Mice
Female
Male
Pyroglyphidae
Mice, Inbred BALB C
Environmental Pollutants
Pregnancy
Hypersensitivity
Prenatal Exposure Delayed Effects
Bronchoalveolar Lavage Fluid
Asthma

Chemicals

Fluorocarbons
Alkanesulfonic Acids
perfluorooctane sulfonic acid
Environmental Pollutants

Word Cloud

Created with Highcharts 10.0.0PFOSmiceHDMexposureinflammationexposeddevelopmentalallergiccountsfemalesulfonicacidsignificantlungexacerbateseosinophilicrisksex-dependenteffectshousedustmiteinduceddayPND3+BALFmacrophageeosinophilcomparedaloneincreasedM2polarizationresponsesDevelopmentalPerfluorooctanelong-chainper-polyfluoroalkylsubstancePFASpersistentorganicpollutantusedaqueousfilm-formingfoamsEmergingepidemiologicalevidenceindicatesbodyburdenobservedlungsFurthermoredysregulatesdevelopmentcriticalfactorsasthmaHoweverunknownwhetherexertsasthmaticprogressionstudytimedpregnantBalb/cJdamsdosedorallyvia10 mg/kg/dspikedvehiclecontrolmealwormsgestationalGD05postnatal21Subsequently30 μg/dayadministeredstarting77-8210 dayssacrificed48 hfinaltreatmentserumconcentrations391 ± 0189 μg/mL567 ± 01676 μg/goffspringrespectivelyMaleshowedhighertotalcellbronchoalveolarlavagefluidFemalepercentagemucousproductionalternativelyactivatedM2-associatedgeneexpressioneffectHDM-inducedIL-4IL-5IL-13RANTESelevatedOveralldatasuggestexacerbatedseveresuggestingairwayperfluorooctaneadultAllergicexposuresMacrophages

Similar Articles

Cited By